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Abstract: Biofilm, a stress-induced physiological state, is an established means of antimicrobial tolerance. A perpetual increase in multidrug resistant (MDR) infections associated with high mortality
and morbidity have been observed in healthcare settings. Multiple studies have indicated that the
use of natural products can prevent bacterial growth. Recent studies in the field have identified that
epigallocatechin gallate (EGCG), a green tea polyphenol, could disrupt bacterial biofilms. A modified lipid-soluble EGCG, epigallocatechin-3-gallate-stearate (EGCG-S), has enhanced the beneficial
properties of green tea. This study focuses on utilizing EGCG-S as a novel synergistic agent with
antibiotics to prevent or control biofilm. Different formulations of EGCG-S and selected antibiotics
were used to study their combinatorial effects on biofilms produced by five potential pathogenic
bacteria, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis,
and Mycobacterium smegmatis. The crystal violet (CV) assay and the sensitive fluorescence-based
resazurin biofilm viability assay were used to assess the biofilm production. Our results identified
optimal formulation for each bacterium, effectively inhibiting biofilm formation to an extent of
95–99%. Colony-forming unit (CFU) and cell viability analyses showed a decrease of viable bacteria. These results depict the potential of EGCG-S as a synergistic agent with antibiotics and as an
anti-biofilm agent.
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1. Introduction
Selective environmental pressures force bacteria to adapt by altering their growth
state. One preferred state is biofilm, which exists in almost 90% of bacteria. Biofilm is a
three-dimensional, multicellular surface-tethered bacterial aggregation embedded in an
extracellular matrix (ECM). During biofilm formation, planktonic cells attach to surface and
transition to the sessile state to secrete an extracellular polymeric substance (EPS) forming a
protective barrier against abiotic and biotic stressors. Upon maturation of biofilm, the cells
are shed for dispersal which then transition into planktonic cells [1]. Biofilm is an inherent
physiological and regulatory strategy for being refractory to antimicrobial treatments and
the host immune system [1,2]. Clinically relevant biofilm-associated infections are either
tissue or device-related infections. Chronic tissue infections include wounds, dental plaque,
urinary tract infection, cystic fibrosis, and so on, while medical devices like catheters,
prosthetic heart valves, orthopedic implants, and so on are colonized by bacteria [3].
Up to 65% and 80% of microbial and chronic infections respectively are linked to bacterial biofilms [4]. Additionally, recurrent bacterial infections are due to the persistent nature
of the biofilms [1]. Currently, ESKAPE group organisms (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and
Enterobacter spp.) are the most prevalent cause of multidrug resistant biofilm-associated
chronic infections [5]. Certain biofilm producers, such as Staphylococcus epidermidis and
the ESKAPE group, have been implicated in nosocomial infections from contaminated
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medical devices [6,7]. Biofilm plays a critical role in the pathogenesis of chronic diseases
like tuberculosis and cystic fibrosis [8]. Treatment of biofilm-associated infections is becoming increasingly difficult due to multidrug resistance, and thereby they still pose a
significant risk to human health. This study focuses on optimizing and evaluating different
formulations to find effective therapeutics for biofilm-related bacterial infections.
Green tea, derived from Camellia sinensis, has held a significant place for a long
time in traditional medicine. It is the second most popular beverage consumed in the
world [9]. Epigallocatechin gallate (EGCG), the most abundant polyphenol/catechin
in green tea, has been attributed numerous health benefits including antioxidant, antiinflammatory, anti-cancerous, and antimicrobial properties [10–13]. United States Food and
Drug Administration (FDA) classified EGCG as a safe compound due to its non-toxic nature
and lack of side effects after application or consumption [14,15]. Many studies indicated
antimicrobial [16,17] and anti-biofilm activity of EGCG on various Gram-positive and
Gram-negative bacteria [18]. Parallel studies suggested synergism of antibiotics and EGCG
on bacterial growth wherein EGCG is shown to enhance bacterial susceptibility, including
methicillin-resistant Staphylococcus aureus (MRSA), Porphyromonas gingivalis (P. gingivalis)
and Klebsiella pneumoniae (K. pneumoniae) to antibiotics [19–23].
Besides the beneficial properties, the natural water-soluble form of EGCG is relatively unstable, which affects its bioavailability and makes formulations difficult [24–26].
The rapid metabolism of EGCG results in a loss of therapeutic properties [19]. Several
modifications of green tea polyphenols (GTPs) were synthesized to resolve the stability
issue. Lipid-soluble analogs were found to be effective GTPs as they were highly stable
with improved bioavailability [27]. Modified lipophilic polyphenols (LTPs) were shown
to act synergistically with antibiotics to inhibit the growth of various Gram-positive and
Gram-negative bacteria [19]. Another lipophilic EGCG derivative, EGCG-palmitate-based
formulations exhibited sporicidal activity [28,29]. Recently, a derivative of EGCG known
as epigallocatechin-3-gallate-stearate (EGCG-S) was synthesized by esterification of fatty
acid making EGCG lipophilic and thereby, enhancing its absorption in the lipid bilayer.
EGCG-S has been successfully shown to inhibit spores produced by Bacillus spp. and the
growth of Streptococcus mutans (S. mutans) [30,31]. Additionally, EGCG-S was shown to
improve the efficacy of antibiotics against various bacteria, thereby making it a potential
synergistic anti-bacterial agent [32]. Various antibiotics have been previously shown to
have synergism with EGCG/EGCG-S to inhibit bacterial growth [32]. The bacteria were
more susceptible to specific antibiotics such as tetracycline and erythromycin respectively
when used in combination with EGCG/EGCG-S [32].
In this study biofilm formation in five potentially pathogenic bacteria, including
Escherichia coli (E. coli), Mycobacterium smegmatis (M. smegmatis), Pseudomonas aeruginosa
(P. aeruginosa), Staphylococcus aureus (S. aureus), and Staphylococcus epidermidis (S. epidermidis)
were studied. E. coli has been implicated in urinary tract infections (UTIs) [33]. The
biofilm associated UTIs are frequently found in patients that use catheters [34,35]. The
non-infectious M. smegmatis was used as a surrogate for M. tuberculosis as they share
growth characteristics [36]. Both strains have been used as model organisms for biofilm
studies [37]. Development of M. tuberculosis biofilm leads to cavity formation and necrosis
in lung tissue [38]. P. aeruginosa is a major cause of nosocomial infections that fail to
resolve with antibiotic treatment. Biofilms of these bacteria are found on implanted and
indwelling devices [39]. S. aureus biofilm is one of the major hallmarks of cystic fibrosis
respiratory infections. These infections have become refractory to antibiotics and have
led to emergence of methicillin-resistant S. aureus (MRSA) [40]. S. epidermidis, a human
commensal microorganism, is a causative agent of chronic infections in compromised
hosts [41]. These infections are associated with the introduction of foreign biomaterials like
catheters and prostheses [42]. All biofilm infections are becoming highly recalcitrant to
host immune system and multiple drugs.
The classic biofilm measurements are based on direct cell enumeration by colony
forming unit (CFU) counting and indirect biofilm accumulation by crystal violet (CV)
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staining. However, these techniques require biofilm resuspension and the potential carryover of the antimicrobials may skew the results [43]. Resazurin assay rapidly quantifies
metabolic cell activity, is sensitive, simple, and requires no biofilm isolation [44]. This
assay is a preferred choice for biofilm quantification [45] and is widely used in biofilmassociated studies [46–48].Therefore, this study utilized three independent quantitative
assays, CFU analysis, CV staining, and resazurin, to ensure consistent data with high
confidence. Furthermore, a fluorescent dye-based microscopic analysis was performed to
study the viability of the cells. According to Clinical Laboratory Standards Institute (CLSI)
Kirby-Bauer disk diffusion [49] profiling results, E. coli and M. smegmatis were intermediate
to erythromycin while P. aeruginosa was resistant to erythromycin. Both S. aureus and
S. epidermidis were intermediate to tetracycline. We previously reported that EGCG-S can
enhance the erythromycin on Gram-negative bacteria such as E. coli, P. aeruginosa and converted the bacteria from antibiotic resistant or intermediate category to sensitive. EGCG-S
can enhance tetracycline on S. aureus and S. epidermidis and converted the bacteria from
antibiotic resistant or intermediate category to sensitive [32]. In this study, erythromycin
was used on the Gram-negative and acid-fast bacteria; tetracycline was used on Grampositive bacteria to study the synergistic action of EGCG-S and erythromycin/tetracycline
in inhibiting biofilm production.
2. Results
2.1. The Effect of Erythromycin and EGCG-S on E. coli Biofilm Formation
The inhibitory effect of erythromycin (E) and EGCG-S (ES) treatments, individually
and/or in combination, on E. coli biofilm formation was evaluated by CFU analysis. Based
on the extent of inhibition, individual lethal dose (LD50 ) for erythromycin and EGCG-S
were identified to be 15 µg/mL (E15) and 50 µg/mL (ES50) respectively. However, since
biofilm is more tolerant to most of the treatment [1,2] it was hypothesized that the abovestated combinations will not be the optimal formulation for inhibiting biofilm production
and thus, numerous combinations of erythromycin (E) and EGCG-S (ES) with variable
concentrations were tested, along with individual treatments. The effect of individual
and combination treatments on biofilm production in E. coli was monitored using colonyforming unit (CFU) assay. CFU measurements were used to calculate log reduction and
percentage of inhibition. On testing the first combination comprising of individual LD50
concentrations (E15+ES50), the log reduction of 1.04 with only 94% inhibition was obtained.
This data strongly suggests that combinations with higher concentrations are required to
inhibit biofilm formation. In comparison to the control, the log reductions and percentage
of inhibition showed by different formulations of E and ES are summarized in Table 1.
Table 1. Colony-forming units (CFU/mL) and respective log reduction and percentage of inhibition
for different treatments on biofilm formation in E. coli. E: erythromycin; ES: epigallocatechin-3-gallatestearate (EGCG-S).
Treatments
(µg/mL)

CFU/mL (Mean ± SD)

Log Reduction

Avg
% Inhibition

E0+ES0
E10
E15
ES50
E10+ES100
E10+ES150
E10+ES200
E15+ES25
E15+ES50

(1.81 ± 0.02) × 106
(1.34 ± 0.09) × 106
(1.10 ± 0.03) × 106
(8.72 ± 0.90) × 105
(3.00 ± 0.23) × 105
(9.00 ± 0.43) × 104
(1.10 ± 0.15) × 105
(1.85 ± 0.10) × 105
(1.65 ± 0.07) × 105

0
0.13
0.22
0.32
0.78
1.30
1.22
0.99
1.04

0
27.01
40.52
53.39
86.07
98.04
96.93
92.65
93.77

Various formulations were tested for their inhibitory effect, and only two combinations
E10+ES150 and E10+ES200 showed the highest log reduction of 1.3 and 1.22, respectively.
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The respective percentage of inhibition was 98% and 97% (p < 0.05). To further strengthen
the CFU data, biofilm quantification was performed using CV and resazurin assay. The
results of the CV analysis are represented in Figure 1A. Both E10+ES150 and E10+ES200
showed approximately 97% inhibition of biofilm using CV assay. However, CV assay is
relatively error-prone, and thus fluorescence measurements using resazurin assay demonstrated that for samples treated with E10+ES150 and E10+ES200, the biofilm formation was
Antibiotics 2021, 10, x FOR PEER REVIEW
significantly inhibited by 94% and 97% respectively, as depicted in Figure 1B. A highly
significant difference compare with the negative control group was found (p < 0.05). Fluorescence microscopy was used to evaluate cell viability of treatment with E10, E15, ES50
and with two formulations, namely E10+ES150 and E10+ES200, as shown in Figure 2.
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Table 3. Colony-forming units (CFU/mL) and respective log reduction and percentage of inhibition for different treatments on biofilm formation in P. aeruginosa. E: erythromycin; ES: EGCG-S.

Treatments

CFU/mL (Mean ± SD)
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2.3. The Effect of Erythromycin and EGCG-S on P. aeruginosa Biofilm Formation
Biofilm formation of P. aeruginosa was evaluated in the presence of multiple concentrations of erythromycin and EGCG-S applied individually to determine E15 and ES50 as LD50 .
In addition, based on CFU assay (Table 3), a treatment combining the LD50 concentrations
E15+ES50 demonstrated a mere 83% inhibition of biofilm production with only 0.61 log
reduction of bacterial cells. Numerous combinations with higher concentrations of E and
ES were further tested for their efficacy in inhibiting biofilm formation. Increased EGCG-S
concentration to 100 µg/mL combined with E15 exhibited the highest log reduction of 0.88
with 95% inhibition of biofilm. Data obtained from CV and Resazurin assays, shown in
Figure 5, identified E15+ES100 as optimal formulation as it inhibited biofilm formation by
97% and 99% respectively. The data within the groups was found to be highly significant
(p < 0.05) compared with the negative control. Supplementary combinations of E15 with
a low concentration of EGCG-S, ES50, gave a 91% inhibition of biofilm formation and
hence, the optimal concentration was confirmed using qualitative bacterial viability assay.
The microscopic images of control and treated samples are shown in Figure 6. The green
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fluorescence of the control sample indicated live bacterial cells in a biofilm. Mixed live and
dead cells were observed in E15, ES25, ES50, E15+ES50 treated samples, while in treatment
with the E15+ES100 formulation bacterial cells in the biofilm were no longer viable. Taken
together, the biofilm formation process in P. aeruginosa is inhibited optimally by E15+ES100
formulation.
Table 3. Colony-forming units (CFU/mL) and respective log reduction and percentage of inhibition
for different treatments on biofilm formation in P. aeruginosa. E: erythromycin; ES: EGCG-S.
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2.4. Synergistic Inhibitory Effect of Tetracycline and EGCG-S on Staphylococcus spp.

2.4. Synergistic Inhibitory Effect of Tetracycline and EGCG-S on Staphylococcus spp.
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Using CV and resazurin assays to quantitively study biofilm formation in S. aureus
identified that TE15+ES200 as the optimal combination exhibiting 97% and 98% inhibition
of S. aureus biofilm respectively as shown in Figure 7. The TE15+ES200 formulation se-
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Table 4. Colony-forming units (CFU/mL) and respective log reduction and percentage of inhibition
for different treatments on biofilm formation in S. aureus. E: erythromycin; ES: EGCG-S.
Treatments
(µg/mL)

CFU/mL (Mean ± SD)

Log Reduction

Avg
% Inhibition

TE0+ES0
TE15
TE30
ES50
ES150
ES200
TE15+ES50
TE15+ES100
TE15+ES150
TE15+ES200
TE15+ES250

(4.41 ± 0.34) × 106
(2.29 ± 0.18) × 106
(2.00 ± 0.16) × 106
(3.18 ± 0.27) × 106
(1.59 ± 0.11) × 106
(2.01 ± 0.15) × 106
(2.20 ± 0.34) × 106
(2.03 ± 0.20) × 106
(9.45 ± 0.37) × 105
(7.75 ± 0.62) × 105
(1.58 ± 0.04) × 106

0
0.29
0.34
0.14
0.44
0.34
0.30
0.34
0.67
0.75
0.45

0
52.65
59.38
30.14
69.40
59.07
57.37
61.73
89.88
94.35
73.53

Table 5. Colony-forming units (CFU/mL) and respective log reduction and percentage of inhibition
for different treatments on biofilm formation in S. epidermidis. TE: tetracycline; ES: EGCG-S.
Treatments
(µg/mL)

CFU/mL (Mean ± SD)

Log Reduction

Avg
% Inhibition

TE0+ES0
TE15
TE30
ES50
ES100
TE15+ES100
TE15+ES200
TE15+ES250
TE15+ES500

(4.72 ± 0.15) × 106
(2.10 ± 0.35) × 106
(2.03 ± 0.16) × 106
(3.15 ± 0.29) × 106
(2.35 ± 0.50) × 106
(1.34 ± 0.23) × 106
(4.78 ± 0.64) × 105
(2.19 ± 0.25) × 105
(1.71 ± 0.01) × 106

0
0.35
0.37
0.18
0.30
0.55
0.99
1.33
0.44

0
55.52
56.95
33.36
50.20
71.69
89.87
95.36
63.72

Using CV and resazurin assays to quantitively study biofilm formation in S. aureus
identified that TE15+ES200 as the optimal combination exhibiting 97% and 98% inhibition
of S. aureus biofilm respectively as shown in Figure 7. The TE15+ES200 formulation severely
affected the viability of S. aureus cells (Figure 8). Similarly, in the case of S. epidermidis as
shown in Figure 9, suggested that a combination of TE15+ES250 is effective in inhibiting
biofilm formation to 99% and 97%, respectively. All quantitative data were subjected to
statistical analyses and found that comparing with negative control was significant at
p < 0.05. Furthermore, microscopic viability analysis demonstrated the death of S. epidermidis cells biofilm on treatment with above-stated combinations when compared to live
cells in control, as shown in Figure 10. In conclusion, the optimal combination of green
tea polyphenol, EGCG-S, and tetracycline that inhibited biofilm formation of S. aureus and
S. epidermidis were found to be TE15+ES200 and TE15+ES250, respectively.
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Figure 7. Effect of single and combinatorial treatments of tetracycline (TE) and EGCG-S (ES) on biofilm formation in
S. aureus. The percentage of inhibition for (A) crystal violet assay and (B) Resazurin assay were calculated from respective
measurement. (-) control: PBS buffer; (+) control: 10% bleach. Experiments were repeated in triplicates. Means are shown
with SD. The percentage of inhibition with different concentrations of tetracycline and EGCG-S indicated that TE10+ES200
inhibits biofilm formation of S. aureus most effectively.
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Figure 8. Fluorescence microscopic observation of cell viability on S. aureus biofilm formation. TE: tetracycline; ES: EGCG-S.
Figure 8. Fluorescence microscopic observation of cell viability on S. aureus biofilm formation
Scale bar = 10 µm. (A) Control, (B) TE15, (C) ES100, (D) ES200, (E) TE15+ES200, and (F) TE15+ES250. The results indicated
tetracycline;
ES: EGCG-S.
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TE15+ES200, and (F) TE15+ES250. The results indicated that TE15+ES200 severely affected the
bility of the cells.
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Figure 9. Effect of single and combined treatments of tetracycline (TE) and EGCG-S (ES) on S. epidermidis biofilm formation.
The percentage of inhibition for (A) crystal violet assay and (B) Resazurin assay were calculated from respective measurement. (-) control: PBS buffer; (+) control: 10% bleach. Experiments were repeated in triplicates. Means are shown with SD.
The percentage of inhibition with different concentrations of tetracycline and EGCG-S indicated that TE10+ES250 inhibits
biofilm formation of S. epidermidis most effectively.
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Figure 10. Fluorescence microscopic observation of cell viability on S. epidermidis biofilm formation. TE: tetracycline; ES:
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the two crucial processes of biofilm formation [56]. Furthermore, this study identified
cell envelope stress as a second target for biofilm interference. Under stress, the cell
downregulates the translation of trans-membrane proteins like protein complexes used in
the biosynthesis of amyloid fibers and cellulose. This stress is potentially induced by the
interaction of EGCG and the cell lipid bilayer [57], which can create temporal disturbances
like perforations and grooves at the cell surface, thereby inducing cell damage [58–60].
EGCG impacts the integrity of the cell envelope, not only in E. coli but also in other
bacteria, including M. smegmatis [61]. Although the trigger for this cell-envelope stress is
unknown, it is proposed that reactive oxygen species (ROS) are involved in the bactericidal
action of catechins [62]. ROS-mediated permanent damage has also been observed in a
combination study of EGCG with antibiotic cefotaxime on E. coli cells [58]. In Staphylococcus
spp. EGCG impairs the assembly of phenol-soluble modulins (PSMs) fibril formation and
targets the preformed fibrils for disentanglement [63]. Another study found flavonoids can
specifically prevent biofilm-associated proteins (Bap)–mediated biofilms [64]. Additionally,
EGCG is shown to interfere with the polysaccharides that form the glycocalyx and bind
peptidoglycan impairing the integrity of the cell wall, thereby suggesting that it can affect
the initial attachment of biofilm to the surface [52]. EGCG has been found to be very
effective in interfering with the action of amyloid fibers, FapC in P. aeruginosa [65] and
amyloid proteins in S. mutans [66]. Besides, EGCG is involved in suppressing multiple
virulence factors deployed by pathogenic bacteria to infections [67,68]. These studies
suggest amyloid fibrils as a common target of EGCG, however EGCG can have multiple
targets for a specific bacterial species and is efficient in interfering with multiple cellular
processes without even entering a bacterial cell.
Some studies have suggested the synergism between EGCG and different antibiotics
on inhibiting bacteria like methicillin-resistant S. aureus (MRSA), P. gingivalis, and K. pneumoniae [22,69,70], and on bacterial biofilms. Biofilm formation by pathogenic organisms
has developed tolerance to elevated levels of antimicrobials [71]. Most studies demonstrate
that EGCG can work synergistically with antibiotics by breaking down the extracellular
matrix components, thereby favoring antibiotics penetration and action on bacterial cells
in biofilms [21–23], while other studies report opposite results [67,72]. These counterproductive effects raise questions about the efficacy of EGCG as its stability and bioavailability
fluctuate with research conditions. EGCG, a hydrophilic molecule with low membrane
permeability and chemical stability [73], is not a suitable candidate to be formulated in
therapeutic preparations without rapid oxidation and loss of antimicrobial activity. Thus,
in this study, we have used a patented (US8076484B2) esterified derivative of EGCG, EGCGStearate (EGCG-S) which improves the bioavailability significantly [74,75]. Previously, we
reported that EGCG-S can be used as an anti-spore agent, as it inhibits germination of
spores produced by Bacillus species [30]. In 2018, our study highlighted the anti-cariogenic
property of EGCG-S as it was able to inhibit the growth and biofilm formation of S. mutans,
an etiological agent of dental caries [31]. Taken together, evidence shows EGCG-S inhibits
spore germination and biofilm formation. However, whether the synergism of EGCG-S
with antibiotics extends to interfere with biofilm formation is still unknown. To the best of
our knowledge, this research is the first to illustrate that the combination of EGCG-S and
antibiotics not only inhibits bacterial growth, but also biofilm formation.
4. Materials and Methods
4.1. Bacterial Cultures
Five potential pathogenic biofilm producers, Escherichia coli (ATCC® CRM-8739),
Pseudomonas aeruginosa (ATCC® CRM-9027), Staphylococcus aureus (ATCC® CRM-6538),
Staphylococcus epidermidis (ATCC® 14990), and Mycobacterium smegmatis (ATCC® 19420)
were grown aseptically on nutrient agar or broth. The stock cultures were stored at 4 ◦ C.
Fresh overnight cultures were maintained at 37 ◦ C with constant shaking at 250 rpm. Gram
staining was performed before each experiment to confirm the culture purity.
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4.2. EGCG-S and Antibiotic Formulations
EGCG-S (US Patent 8076484) purchased from Camellix LLC (Evans, GA, USA), was
dissolved in absolute ethanol to make a stock concentration of 10 mg/mL prior to formulations. The stock was diluted to the required concentrations for each experiment. Phosphate
buffer saline (PBS) was used as a negative control, while 10% bleach was used as a positive
control. Antibiotics erythromycin (E0774) and tetracycline (T3258), were purchased from
Sigma Aldrich (St. Louis, MO, USA). The stock concentration (1000 µg/mL) was prepared
by dissolving antibiotics in absolute ethanol. Final concentrations of ethanol in the working
solutions were all less than 5%, which did not inhibit the growth of the bacteria. The
solutions were filter sterilized and stored at −20 ◦ C. The required concentrations were
diluted from the stock aseptically prior to the experiment. The formulations consisted of
varying concentrations of EGCG-S and antibiotics depending on the selected bacterium.
4.3. Quantitative Absorbance-Based Biofilm Measurement (Crystal Violet Assay)
The cultures were treated with EGCG-S and antibiotics alone and different formulations followed up by incubation at 37 ◦ C for 4 days. The liquid was aspirated, the biofilm
(if any) was washed and then stained with 0.1% crystal violet (CV) for 24 h. After strain
aspiration and a final 1 × PBS wash, the biofilms were dried for 24 h. Biofilm was resuspended in 30% acetic acid and the optical density (OD) were recorded at 595 nm [76]. All
experiments were performed in triplicate, with mean and standard deviation calculated.
These readings were then used to determine the percentage of biofilm inhibition. 10%
bleach and PBS were used as the positive and negative control, respectively.
Percentage of Inhibition = [(ODUntreated − ODTreated )/ODUntreated ] × 100

(1)

4.4. Quantitative Fluorescence-Based Biofilm Measurement (Resazurin Assay)
Fresh log-phase bacterial cultures were incubated at 37 ◦ C for 4 days in 96-well plates.
After the media was aspirated, the biofilm was rinsed with 1 × PBS and stained with a
200 µM Resazurin solution. After overnight incubation in the dark at 4 ◦ C, fluorescence
was measured at excitation and an emission wavelength of 560 nm and 590 nm respectively
using a microplate reader (Infinite 200 PRO, Tecan, Männedorf, Switzerland) adjusted to the
fluorescent mode [47]. The Relative Light Units (RLU) were measured, and the percentage
(%) of inhibition was calculated for each treatment according to the following formula.
Percentage of Inhibition = [(RLUUntreated − RLUTreated )/RLUUntreated ] × 100

(2)

4.5. Quantitative Growth-Based Cell Viability Measurement (Colony Forming Unit Assay)
Bacterial cultures were incubated at 37 ◦ C for 4 days in 24-well plates. The biofilm
attached to the well plate was scrapped and suspended in 100 µL of deionized water.
The samples were serially diluted (from 100 to 10−4 ) and 100 µL of each dilution was
spread plated on nutrient agar aseptically. The media plates were incubated overnight
at 37 ◦ C. Colony-forming units (CFUs) were recorded and percentage of inhibition was
calculated using the following formula. LD50 represents the lethal concentration to 50% of
the population.
Percentage of Inhibition = [(CFUUntreated − CFUTreated )/CFUUntreated ] × 100

(3)

Additionally, the CFU measurement was used to calculate log10 (fold) reduction using
the following equation:
Log Reduction = Log10 (CFUControl /CFUTreated )

(4)

4.6. Qualitative Microscopy-Based Cell Viability Assay
The LIVE/DEAD® BacLight™ Bacterial Viability Kit (Thermo Fisher, Waltham, MA,
USA) was used according to the manufacture manual. The scrapped biofilms were grown
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in a 6-well plate with/without different treatments. After incubation at 37 ◦ C for 4 days, the
liquid was aspirated exposing the biofilms adhering to the well surface. The biofilms were
then washed and stained with dye mixture. After proper staining coverslips were placed in
the well to view under the microscope. The molecular probes used were SYTO 9, a greenfluorescent membrane-permeant dye that stains live cell, and propidium iodide (PI), red
fluorescence dye that stains dead cells due to damaged cell membrane. All samples were
viewed under a fluorescent microscope (Axio Scope A1, Carl Zeiss, München, Germany).
4.7. Statistical Analysis
All assays were performed in triplicate. Statistically significant differences between
control and test were analyzed by one-way analysis of variance (one-way ANOVA) with
Dunnett’s multiple comparison post-test at p < 0.05. The analyses were carried out in
GraphPad Prism Software (GraphPad Software Inc., San Diego, CA, USA).
5. Conclusions
This study successfully demonstrated the synergistic inhibitory effects of a modified
green tea polyphenol, EGCG-S, in combination with antibiotics on biofilm formation in
five distinct potential pathogenic bacteria. Inhibition of biofilm formation was determined
after an initial assessment of the inhibitory nature of EGCG-S and antibiotics on the growth
of the cells. The LD50 of erythromycin for all Gram-negative bacteria (E. coli, M. smegmatis,
and P. aeruginosa) is 15 µg/mL. The LD50 of EGCG-S is 50 µg/mL for E. coli and P. aeruginosa: 100 µg/mL for M. smegmatis. As for both Gram-positive bacteria (S. aureus and
S. epidermidis), LD50 is 15 µg/mL for tetracycline and 50 µg/mL for EGCG-S. The optimal
formulation of EGCG-S and antibiotics specific for every bacterium tested was determined
by the combinatorial analysis of quantitative measurements from three different assays
(CFU, CV, and resazurin). The colony-forming unit (CFU) assay provided preliminary
information on the concentrations, of EGCG-S and antibiotics, necessary for their effects
on biofilm formation. Although CFU data, indicating log-reduction of about 1.0, is not
enough to strongly support synergism, it does reflect similar trends in comparison with
the crystal violet (CV) and Resazurin assay. These experiments confirmed that EGCG-S in
combination with antibiotics was able to maximally reduce biofilm formation in pathogenic
bacteria. The findings were further confirmed by qualitative cell viability analysis and the
optimal formulation for each bacterium was determined.
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